Acumen Pharmaceuticals, Inc.
ABOS
$2.70
$0.020.56%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
4/5/2026
-
TipRanks Financial Blog
4/5/2026
-
TipRanks Financial Blog
3/31/2026
-
Zacks Investment Research
3/31/2026
-
Zacks Investment Research
3/31/2026
-
Ticker Report
3/30/2026
-
Zacks Investment Research
3/30/2026
-
Zacks Investment Research
3/29/2026
-
MarketBeat
3/27/2026
-
MarketBeat
3/26/2026
-
Seeking Alpha: Transcripts
3/26/2026
-
SeekingAlpha
3/26/2026
-
Ticker Report
3/26/2026
-
MarketBeat
3/26/2026
-
MarketBeat
3/26/2026
-
MarketBeat
3/26/2026
-
TipRanks Financial Blog
3/26/2026
-
Globe Newswire
3/23/2026
-
MarketBeat
3/21/2026
-
MarketBeat
3/19/2026
-
Globe Newswire
3/19/2026
-
MarketBeat
3/18/2026
-
Tickeron - Technical Analysis
3/17/2026
-
MarketBeat
3/17/2026
-
Globe Newswire
3/17/2026
-
Tickeron - Technical Analysis
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, March 26, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 344 4190
Address
1210-1220 Washington St.
Newton, MA 02465
Newton, MA 02465
Country
Year Founded
Business Description
Sector
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted...
more